One-Offs Lift Dr Reddy’s In Q2
Indian Firm Is Eyeing US Opportunities For Its Rival To Suboxone
One-offs aided Dr Reddy’s performance in the second quarter although US growth was flat amid challenges including the recall of ranitidine. But the Indian firm is enthused about fresh potential opportunities for generic Suboxone in the US in view of Indivior’s intent to discontinue its authorized generic.
You may also be interested in...
US Generics Market Continues To Seek Stability
As the US generics market continues to experience turbulence, the industry’s largest players are adopting a wide range of strategies to cope with the uncertainty as signs of stabilization begin to emerge.
Ready, Set, Lowest: Who Won China’s Latest Drug Bidding War?
Multinationals are feeling the heat to win in China's latest drug procurement battle. The winning prices have surprised even previous winners and may have a profound and long-lasting impact on the pharma sector.
Reddy’s Will Look For Acquisitions Under New CEO Israeli
With Erez Israeli set to step up from COO to CEO, Dr Reddy’s is looking to leverage its lack of debt and strong cash flow in the mergers and acquisitions arena.